News | November 17, 2010

Lunch Symposium to Highlight Medical Simulation Technology

November 17, 2010 – A lunch symposium detailing the evidence for simulation in medical training and other fields will be sponsored by W.L. Gore and Associates at the VEITHsymposium. The EVEResT (European Virtual Reality Endovascular Research Team) lunch symposium will take place Nov. 19 from 12:00 to 1:00 p.m. in the Gramercy A room, second floor.

Companies will demonstrate how new simulation technologies are designed to enhance performance in endovascular procedures.

Rapid advances in technology and a demand for increased patient safety have led to a growing interest in simulation as a training tool for complex procedures. As a result, some of the world’s leading vascular surgeons and radiologists are participating in the event.

It is chaired by Nicholas Cheshire, M.D., professor of vascular surgery, head of circulation sciences and renal medicine, Imperial College Healthcare, Campus St. Mary’s Hospital, London; Mario Lachat, M.D., head of cardiovascular surgery, University Hospital, Zurich, Switzerland; and Isabelle van Herzeele, M.D., Ph.D, consultant at the department of thoracic and vascular surgery at Ghent University Hospital, Belgium and Honorary Fellow at the department of biosurgery and surgical technology NHS Trust, Campus St. Mary's Hospital, London.

The group was founded involving three academic centers and the three specialties (cardiology, radiology, vascular surgery) involved in endovascular treatments of vascular diseases. This collaboration is intended to inspire other academic centers, professional societies and medical device companies to work together and develop a standardized approach for endovascular training and assessment.


Related Content

News | Cardiovascular Clinical Studies

May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

Home May 02, 2024
Home
News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
Subscribe Now